Skip to main content
. 2009 Sep;2(5):291–297. doi: 10.1177/1756285609337992

Figure 2.

Figure 2.

Clinical response to daclizumab treatment based on annual relapse rate (ARR). Pretreatment and during treatment ARR was compared for all relapsing—remitting patients (n = 12). The ARR decreased from 2.15 relapses per year in pretreatment observations to 0.33 relapses per year during sustained therapy (p < 0.0001 by unpaired t-test; p < 0.0001 by unpaired f-test).